Form D · Biotechnology
nference, inc.
Cambridge, MA · CIK 0001806274
Offering snapshot reported Nov 4, 2022 · SEC filing
- Reported sold
- $2.74M Offering amount: $2.74M
- Investors reported
- 72 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 21, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 4, 2022 | Initial | $2,744,005 | No comparison | 72 | SEC filing |
| Mar 12, 2020 | Initial | $9,600,590 | No comparison | 57 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-463954
Source: Form D, filed Nov 4, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Murali Aravamudan | Director, Executive |
| Tim Barrows | Director |
| Andrew Danielsen | Director |
| Harris Fishman | Executive |
| David Goel | Director |
| John Halamka | Director |
| Agustin Marquez | Executive |
| Thomas Mc Naughton | Executive |
| Ajit Rajasekharan | Executive |
| Venkataramanan Soundararajan | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Main Street Suite 400, East Arcade, 4 Th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142